Hemab Therapeutics Holdings, Inc. has 9 Schedule 13D or 13G filings on record since 2026-05-08. 9 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 16.6% | 7,729,773 | SCHEDULE 13G, 2026-05-11 | 2026-05-04 |
| Ai Den-Mab LLC | 10.4% | 4,876,344 | SCHEDULE 13D, 2026-05-11 | 2026-05-04 |
| Novo Holdings A/S | 9% | 4,180,550 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Deep Track Capital, LP | 8.15% | 3,600,996 | SCHEDULE 13G, 2026-05-08 | 2026-05-01 |
| Fmr LLC | 7.9% | 3,697,837 | SCHEDULE 13G, 2026-08-06 | 2026-06-30 |
| Capital International Investors | 7.7% | 3,603,876 | SCHEDULE 13G, 2026-08-12 | 2026-06-30 |
| Behzad Aghazadeh | 7.06% | 3,298,236 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Sofinnova Crossover II SLP | 5.4% | 2,511,212 | SCHEDULE 13G, 2026-08-05 | 2026-06-30 |
| Raymond Debbane | 5.1% | 2,366,235 | SCHEDULE 13G, 2026-08-07 | 2026-08-03 |
Purpose of Transaction (Item 4)
Ai Den-Mab LLC
The Reporting Persons who hold Common Stock directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Subject to the terms of the Investors' Rights Agreement (as defined below), the Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional Common Stock in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations under applicable law. The Reporting Persons have not yet determined which, if any, of the above courses of action they may ultimately take. The Reporting Persons' future actions with regard to the Issuer are dependent on their evaluation of the factors listed above, circumstances affecting the Issuer in the future, including prospects of …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-11; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-08 | Deep Track Capital, LP | 8.15% | SCHEDULE 13G |
| 2026-05-11 | Ai Den-Mab LLC | 10.4% | SCHEDULE 13D |
| 2026-05-11 | RA Capital Management, L.P. | 16.6% | SCHEDULE 13G |
| 2026-08-05 | Sofinnova Crossover II SLP | 5.4% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 7.9% | SCHEDULE 13G |
| 2026-08-07 | Raymond Debbane | 5.1% | SCHEDULE 13G |
| 2026-08-12 | Capital International Investors | 7.7% | SCHEDULE 13G |
| 2026-08-14 | Behzad Aghazadeh | 7.06% | SCHEDULE 13G |
| 2026-08-14 | Novo Holdings A/S | 9% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Hemab Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.